Perindopril

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Perindopril is a novel angiotensin-converting enzyme (ACE) inhibitor approved in the US.
• It requires conversion to its active metabolite, perindoprilat.
• Its extended duration of action permits once-daily dosing.

Purpose of the Study:

• To review clinical trials on perindopril for essential hypertension, alone and in combination therapy.
• To examine perindopril's efficacy in treating congestive heart failure.
• To discuss perindopril's effects on arterial wall properties, tolerability, drug interactions, and dosage.

Main Methods:

• Review of clinical trials involving perindopril in patients with essential hypertension.
• Evaluation of studies assessing perindopril for congestive heart failure.
• Analysis of data on perindopril's impact on arterial properties and safety profile.

Main Results:

• Perindopril demonstrates efficacy in treating essential hypertension, both as monotherapy and in combination with other antihypertensives, particularly thiazide diuretics.
• Clinical trials support the use of perindopril for managing congestive heart failure.
• The drug influences arterial wall properties and exhibits acceptable tolerability with manageable drug interactions.

Conclusions:

• Perindopril is an effective ACE inhibitor for essential hypertension and congestive heart failure, offering the convenience of once-daily administration.
• Its favorable pharmacokinetic profile and demonstrated clinical benefits support its role in cardiovascular therapy.
• Further review of tolerability, interactions, and dosing confirms its clinical utility.